Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-29, Stock:ABBV, The news for the past five days is as follows:
2019-03-22: NEWS1: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS2: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS3: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS4: Better Buy: AbbVie vs. Eli Lilly.NEWS5: Better Buy: AbbVie vs. Eli Lilly.NEWS6: Better Buy: AbbVie vs. Eli Lilly.
2019-03-25: NEWS1: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS2: 4 Blockbuster Drug Launches to Watch in 2019.NEWS3: 4 Blockbuster Drug Launches to Watch in 2019.
2019-03-26: NEWS1: AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan.NEWS2: AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan.NEWS3: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS4: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS5: AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan.NEWS6: Were Hedge Funds Right About AbbVie Inc (ABBV)?.NEWS7: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs.NEWS8: AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan.NEWS9: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS10: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.
2019-03-27: NEWS1: How this cancer-fighting startup switched gears, landed a big deal and started a clinical trial.
2019-03-28: NEWS1: AbbVie's big acquisition blowup: A one-off or an omen?.NEWS2: Analysts Have Mixed Opinions on AbbVie in March.NEWS3: Drug giant cutting 178 jobs, three years after buying Peninsula biotech for $6 billion.NEWS4: Real Estate Deals of the Year: AbbVie lease.

Answer: Rise